Newsfeeds - Spark Newswire

1 minute read

Morgan Stanley Initiates Coverage On Cytek Biosciences with Equal-Weight Rating, Announces Price Target of $26

August 17, 8:10 AM

Morgan Stanley analyst Tejas Savant initiates coverage on Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight rating and announces Price Target of $26.

CTKB

1 minute read

Goldman Sachs Initiates Coverage On Cytek Biosciences with Buy Rating, Announces Price Target of $28

By Benzinga Newsdesk

August 17, 6:12 AM

Goldman Sachs analyst Matthew Sykes initiates coverage on Cytek Biosciences (NASDAQ:CTKB) with a Buy rating and announces Price Target of $28.

CTKB

1 minute read

Piper Sandler Initiates Coverage On Cytek Biosciences with Overweight Rating, Announces Price Target of $28

By Benzinga Newsdesk

August 17, 5:29 AM

Piper Sandler analyst Steven Marotta initiates coverage on Cytek Biosciences (NASDAQ:CTKB) with a Overweight rating and announces Price Target of $28.

CTKB

5 minute read

60 Biggest Movers From Yesterday

By Lisa Levin

August 17, 5:12 AM

Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 33.7% to close at $3.37 on Monday after the company announced plan to expand product portfolio with introduction of Painshield relief for over-the-counter use and plans for future product launch.

ABSI

3 minute read

The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow

By Shanthi Rexaline

August 15, 11:05 AM

Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among those reporting during the week.

ABSI